Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9113673 | 0.92 | ACACB (0.56) | ACACAACACB | |
| SCHEMBL9113488 | 0.92 | ACACB (0.48) | ACACAACACB | |
| SCHEMBL9113010 | 0.90 | ACACB (0.47) | ACACAACACB | |
| SCHEMBL9111434 | 0.89 | ACACB (0.49) | ACACAACACB | |
| SCHEMBL9112899 | 0.89 | ACACB (0.46) | ACACAACACB | |
| SCHEMBL16612737 | 0.84 | MEN1 (0.39) | ACACB | |
| SCHEMBL9111286 | 0.84 | ACACB (0.56) | ACACAACACB | |
| Hydrochloric Acid SCHEMBL9111977 | 0.83 | MEN1 (0.39) | ACACB | |
| SCHEMBL9113969 | 0.81 | ACACB (0.52) | ACACAACACB | |
| SCHEMBL9111884 | 0.81 | ACACB (0.46) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| WO-2012074126-A9 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-06 | — | — | WO | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074126-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | ACACA 1/4885ACACB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.